What You Should Know:
– VivoSense, an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data raises $25 Million in Series A funding.
– The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments. VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital clinical outcome assessments (COAs) for life science research.
Wearable Sensor Biomarkers that Advance Clinical Research
Data captured by wearable sensors will play an increasingly important role in pharma and biotech, and VivoSense is poised to become a leader in developing validated clinical biomarkers and clinical outcome assessments (COAs) for use in registrational studies and regulatory approvals. VivoSense is an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data. True to its name, using its proprietary software, VivoSense “makes sense” of the myriad of biological signals that make up a patient’s physiology. These include physical activity, sleep, temperature, blood glucose levels, respiration, and cardiac function. VivoSense interprets and contextualizes data gathered directly from the patient and makes it available to clinical researchers in pharma and biotechnology.
“This strategic investment from Debiopharm and the Perceptive Xontogeny Venture (PXV) Fund will allow VivoSense to accelerate the development of real-world digital clinical measures from wearable and remote monitoring technologies,” said Dudley Tabakin, chief executive officer of VivoSense. “Measures that are trusted and valued by all stakeholders are the foundation on which all other innovation in digital health must be based. VivoSense is working to realize the potential of novel measures and technologies in regulatory and medical decision making to leverage real-world data at scale and bring life-saving treatments to the patients who need them most.”
